Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leptin antibody
- Development stage
- Preclinical
- Lead developer
- UT Southwestern Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
A first-in-class humanized monoclonal neutralizing antibody targeting leptin. It is designed to disrupt the obesity-breast cancer axis by inhibiting leptin-mediated proliferation of estrogen receptor-positive (ER+) breast cancer cells, particularly those resistant to endocrine therapy (ET) and CDK4/6 inhibitors. In preclinical xenograft models, it has demonstrated the ability to inhibit tumor growth as a single agent and show synergy when combined with endotrophin antibodies or palbociclib.
- Other names
- anti-leptin antibodyhumanized monoclonal leptin antibody
02
Targets
LEPR (Leptin receptor)
Beyond the preview
Go deeper on leptin antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leptin antibody.